LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

Cerrado

4.51 -6.24

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.48

Máximo

4.8100000000000005

Métricas clave
By Trading Economics
Ingresos	-29K -20M
Ventas	701K 2M
BPA	-0.15
Margen de beneficios	-993.186
Empleados	69
EBITDA	-2.5M -22M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+103.93% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	59M 691M
Apertura anterior	10.75
Cierre anterior	4.51

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.28 / 1.33 Soporte y Resistencia

Aclaris Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 may 2026, 16:02 UTC

Ganancias

Principales Movimientos del Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 may 2026, 14:55 UTC

Principales Movimientos del Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 may 2026, 14:43 UTC

Principales Movimientos del Mercado

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 may 2026, 17:28 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 may 2026, 16:24 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 15:55 UTC

Charlas de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2026, 15:20 UTC

Charlas de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 may 2026, 15:20 UTC

Ganancias

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 may 2026, 14:33 UTC

Charlas de Mercado

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparación entre iguales

Cambio de precio

Aclaris Therapeutics Inc previsión

Precio Objetivo

By TipRanks

103.93% repunte

Estimación a 12 Meses

Media 10.38 USD 103.93%

Máximo 16 USD

Mínimo 4 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Aclaris Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Aclaris Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.28 / 1.33Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.